Allergy Therapeutics (LON:AGY) Share Price Passes Below 200 Day Moving Average – Here’s Why

Shares of Allergy Therapeutics plc (LON:AGY) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 10.44 and traded as low as GBX 7.22. Allergy Therapeutics shares last traded at GBX 7.48, with a volume of 131,015 shares traded.

Allergy Therapeutics Stock Performance

The stock’s 50 day simple moving average is GBX 9.21 and its two-hundred day simple moving average is GBX 10.39. The stock has a market capitalization of £443.28 million, a PE ratio of -7.22, a PEG ratio of -30.70 and a beta of 0.85. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. The company had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. On average, sell-side analysts expect that Allergy Therapeutics plc will post -2.56 EPS for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.